Two novel simple and rapid liquid–liquid and solid phase extraction methods have been developed for determination of olmesartan in human plasma using zidovudine as an internal standard. Liquid–liquid extraction from spiked human plasma samples was done using Dichloromethane: acetic acid (5.5: 0.5, v/v) solvent, while solid phase extraction was carried out on a DSC MCAX cartridge. For HPLC, the mobile phase consisted of water acetic acid pH 4.5 and methanol (25:75) at a flow rate of 0.5 mL · min−1 in isocratic mode. The calibration curve was plotted with a concentration range 10 μgmL−1 to 60 μgmL−1. Recovery studies were carried out by LLE and SPE procedures with average recoveries 69.27% and 72.87%, respectively. For HPTLC the developing phase consisting of ethyl acetate methanol and acetic acid (8.0:2.0:0.05 v/v/v) and detection was carried out on 269 nm. The calibration curve was plotted over the concentration range of 200 ng to 600 ng. The average recoveries were 90.12% and 79.64% by LLE and SPE, respectively. The proposed method was validated as per US-FDA guidance.
Keywords: HPTLC; human plasma; liquid–liquid extraction; Olmesartan Medoxomil; RP-HPLC; solid phase extraction
Olmesartan Medoxomil a prodrug of Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. It blocks the vasoconstrictor effect of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in the vascular smooth muscle. Chemically it is 1-((2′-(1H-tetrazol-5-yl) biphenyl-4-yl) methyl)-2-butyl-4-(2-hydroxypropan-2-yl)-4, 5-dihydro-1H-imidazole-5-carboxylic acid.
Olmesartan Medoxomil was supplied by Ajanta Pharma Ltd. (Paithan, India). Zidovudine was received from Emcure Pharma Ltd. (Pune, India). The methanol, glacial acetic acid, ammonia (liquor), acetonitrile and dichloromethane were procured from Qualigens Fine Chemicals Ltd. Ethyl acetate was purchased from S d Fine Chem. Ltd. (Mumbai, India). Drug free human plasma was procured from Arpan Blood Bank (Nashik, India).
The HPLC system was equipped with binary pumps Smartline-1000–1, 2, and Smartline-UV-2600 data were acquired and processed using Chromgate 3.1 software (all were from Knauer, Berlin, Germany). For HPTLC, the samples were applied using Linomat V sample applicator with a Camag 100 µL syringe. The densitometry scanning was performed by using a Camag TLC scanner III supported by win CATS software (Camag, Muttenz, Switzerland).
HPLC measurements were carried out using a reverse phase Eurosphere-100 C18 (250 mm × 4.6 mm × 5µ) column operated at ambient temperature isocratically at 0.5 mLmin
Graph: FIGURE 1 Chromatogram of pure Olmesartan (tR6.8) and Zidovudine (tR8.8).
Chromatographic separation with HPTLC was performed using a precoated silica gel plate 60 F
Graph: FIGURE 2 Chromatogram of pure Olmesartan (Rf 0.29) and Zidovudine (Rf 0.60).
For HPLC in each 15 mL centrifuge tube, the stock solution (1.0 mgmL
After 30 min, for LLE in CS and QC samples, protein precipitation was done with acetone and extracted using 5.5 mL dichloromethane and 0.5 mL acetic acid as extracting solvent. For the SPE technique, 0.5 mL acetic acid was added in each tube to avoid anion formation. For protein precipitation 2 mL acetonitrile was added in each tube.
Further, these samples were vortexed on a mixer for 1 min and then centrifuged at 10,000 rpm for 5 min.
In the LLE procedure, the organic phase was recovered and evaporated to dryness in a water bath at 50°C. The mass was reconstituted with 1 mL mobile phase. In SPE, the supernatant mixture after centrifugation was loaded to DSC MCAX SPE column (1 g), which was pretreated with 1 mL of methanol first, followed by 1 mL of acetic acid (pH 2.6). The column was vacuumed to dryness and the analytes were eluted with 1 mL of 10% ammonium hydroxide in methanol.
For HPTLC, in a 15 mL centrifuge tube the volume from the stock solution (1 mgmL
The proposed method was validated for selectivity, sensitivity, accuracy, precision, recovery, linearity, and stability according to the USFDA Guidance for the validation of bioanalytical methods.
TABLE 1 Summary of Validation Parameters
HPLC HPTLC Parameters LLE SPE LLE SPE Linearity range 10–60 µgmL−1 80–600 ng Correlation co-efficient 0.9690 0.9630 0.9900 0.9820 LLOQ 10 µgmL−1 80 ng Extraction Efficiency (% Recovery) 69.27 72.87 90.12 79.64 Accuracy (% RE) i. Low 1.00 9.56 11.89 6.76 ii. Mid 12.60 3.65 2.53 3.83 iii. High 1.72 12.88 0.65 7.14 Precision (CV) 1. Inter day i. Low 3.75 2.29 3.29 3.00 ii. Mid 2.01 1.56 1.02 1.51 iii. High 0.74 0.84 1.11 0.69 2. Intra day i. Low 5.02 2.94 2.59 2.86 ii. Mid 2.64 1.04 1.07 1.13 iii. High 0.89 0.78 1.04 0.72
Interfering peaks were not observed in the chromatogram of blank pooled human plasma. Typical chromatograms were obtained from drug free human plasma (blank sample) and plasma sample spiked at lower limit of quantitation (LLOQ) (80 ng) with internal standard.
The accuracy and precision at the lower limit of quantitation (LLOQ) was analysed by using five replicates of the sample. Peak response was considered for the calculations and it was determined as peak area ratio. The sensitivity is determined by % relative error and coefficient of variance at LLOQ (80 ng).
Accuracy and precision of the method was determined by repeatability (intra-day) and intermediate precision (inter-day) for the set of quality control samples (low, mid, high) in replicate. The results revealed excellent intra and inter day accuracy and precision of the method, which is within the acceptable limit.
Absolute recovery was calculated by comparing peak areas obtained from freshly prepared samples extracted with unextracted standard solutions of the same concentration. Recovery data was determined in triplicates at three concentrations as recommended by the FDA guidelines.
The linearity was evaluated by linear regression analysis, which was calculated by the least square regression method. The linearity of Olmesartan was determined at five concentration levels ranging from 10 to 60 µgmL
TABLE 2 Linearity and Calibration Data of Olmesartan by HPLC Method (n = 5)
Mean Peak Response ± Concentration (µgmL−1) LLE SPE 10 0.4602 ± 0.032425, ±7.045 0.8849 ± 0.04778, ±5.339 20 0.8801 ± 0.01679, ±1.908 2.2418 ± 0.040277, ±1.797 30 1.2509 ± 0.056721, ±4.535 3.5590 ± 0.105109, ±2.953 40 1.7821 ± 0.045834, ±2.572 4.2236 ± 0.044721, ±1.059 50 1.9966 ± 0.01837, ±0.920 4.8083 ± 0.035493, ±0.738 60 2.1373 ± 0.012019, ±0.562 7.0880 ± 0.176063, ±2.484
TABLE 3 Linearity and Calibration Data of Olmesartan by HPTLC Method (n = 3)
Mean Peak Response ± Concentration (ng) LLE SPE 80 0.2303 ± 0.00502, ±2.180 0.4299 ± 0.001131, ±0.263 200 0.5415 ± 0.005374, ±0.992 0.9464 ± 0.00396, ±0.417 300 0.7486 ± 0.013081, ±1.748 1.2600 ± 0.002192, ±0.174 400 1.0203 ± 0.001414, ±0.139 1.5238 ± 0.031891, ±2.062 500 1.2638 ± 0.007425, ±0.588 1.9571 ± 0.017395, ±0.894 600 1.5622 ± 0.010253, ±0.656 2.4499 ± 0.084146, ±3.353
Graph
Stability of Olmesartan in plasma at various conditions was evaluated at low and high QC concentrations. Stability presented by calculating the difference of the percentage recoveries between freshly prepared samples and that of quality control samples are shown in Table 4.
TABLE 4 Stability of Olmesartan (n = 3)
HPLC HPTLC Stability (% Recovery Differences from Fresh Extract) LLE SPE LLE SPE Bench top i. Low QC −2.10 −7.90 −9.61 4.49 ii. High QC −5.79 −2.16 −2.31 0.10 Freeze thaw i. Low QC −2.89 −8.10 −0.15 7.78 ii. High QC −6.38 −1.02 −2.81 2.23 Post preparative i. Low QC −3.63 1.14 −1.06 4.92 ii. High QC −6.47 −2.09 −2.33 0.54
The proposed HPLC and HPTLC methods were simple, rapid, accurate, and precise for estimation of Olmesartan from human plasma. Both extraction procedures give satisfactory and reproducible recovery of Olmesartan from human plasma. Among these two extraction procedures, LLE is more suitable as it gives high recovery as compared to SPE.
We acknowledge Ajanta Pharma Ltd. (Paithan, India) and Emcure Pharma Ltd. (Pune, India) for providing gift samples of Olmesartan Medoxomil and Zidovudine, respectively. We would like to thank Arpan Blood Bank, (Nashik, India) for providing human plasma for the research work. Authors are thankful to Prof. V. M. Aurangabadkar, Principal, M. G. V.'s Pharmacy College, Nashik for providing the necessary facilities for the research work.
By SantoshR. Tambe; RupaliH. Shinde; LalitR. Gupta; Vikas Pareek and SantoshB. Bhalerao
Reported by Author; Author; Author; Author; Author